| Previous Close | 3.03 |
| Open | 3.04 |
| Bid | 3.04 x 1600 |
| Ask | 3.05 x 12500 |
| Day's Range | 2.96 - 3.06 |
| 52 Week Range | 0.50 - 3.30 |
| Volume | 1,178,761 |
| Avg. Volume | 6,029,510 |
| Market Cap | 442.76M |
| Beta | 1.40 |
| PE Ratio (TTM) | -8.00 |
| EPS (TTM) | -0.38 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
Capital Cube•2 days agoAVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)
- ACCESSWIRE•3 days ago
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals Inc. and Tandem Diabetes Care Inc.
NEW YORK, NY / ACCESSWIRE / August 15, 2017 / U.S. markets rebounded sharply Monday as geopolitical tensions eased after Secretary of State Rex Tillerson and U.S. Secretary of Defense James Mattis commented ...
- Zacks•8 days ago
AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.
